Inventiva announced the publication of preclinical study results in Biomedicine & Pharmacotherapy, demonstrating that lanifibranor may reduce Portal Hypertension (PH). The study, a collaboration with Ghent University Hospital, evaluated lanifibranor's effect on PH independently of hepatic condition using two distinct mouse models.
In the Partial Portal Vein Ligation (PPVL) model, lanifibranor reduced portal pressure in a dose-dependent and statistically significant manner, with decreases of 28% at 10mg/kg and 39% at 30mg/kg. This improvement was attributed to vascular amelioration within the splanchnic compartment, including reduced blood flow and decreased vascular wall thickness.
In the common Bile Duct Ligation (cBDL) model, lanifibranor also reduced portal pressure and spleen weight dose-dependently, alongside an improvement in fibrosis. These findings suggest lanifibranor's potential to ameliorate PH by addressing both intra-hepatic conditions like fibrosis and extra-hepatic conditions such as mesenteric vasculature expansion through its anti-angiogenetic effects.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.